# Quality Review: TP53 Synthetic Lethality Report

**Report reviewed**: `tp53-synthetic-lethality-report.md`
**KG JSON reviewed**: `tp53-synthetic-lethality-kg.json`
**Review date**: 2026-03-03
**Reviewer**: Fuzzy-to-Fact Quality Review Framework v1.0

---

## Summary Verdict

- **Overall**: **PASS** (with minor presentation gaps)
- **Template**: Template 1 — Drug Discovery / Repurposing (confirmed by Drug Candidates table with phases, mechanisms, and evidence levels)
- **Top issues**:
  1. Compound CURIEs use custom format (COMPOUND:ADAVOSERTIB) rather than canonical CHEMBL CURIEs
  2. Disease entity absent from Resolved Entities table (disease associations present in a separate section with MONDO/EFO IDs, but not as a formal resolved entity row)
  3. LOCATE steps not explicitly cited in Resolved Entities table — report cites RETRIEVE tools (hgnc_get_gene, entrez_get_gene) but not the preceding search calls

---

## Dimension Scores

| # | Dimension | Score | Notes |
|---|-----------|-------|-------|
| 1 | CURIE Resolution | **PARTIAL** | 8 genes resolved with proper CURIEs (6 HGNC, 2 NCBIGene). Compounds use custom format, not CHEMBL CURIEs. |
| 2 | Source Attribution | **PASS** | >95% of claims cite `[Source: tool(param)]`. Tables, mechanism rationale, and gaps all sourced. |
| 3 | LOCATE→RETRIEVE | **PARTIAL** | RETRIEVE steps cited; LOCATE (search) steps not explicitly shown in report. KG confirms entities were properly located. |
| 4 | Disease CURIE | **PARTIAL** | MONDO/EFO IDs present in Disease Associations section. No disease row in Resolved Entities table. KG has disease_associations object but no formal disease nodes. |
| 5 | OT Pagination | **PASS** | Open Targets GraphQL used via curl for knownDrugs. No pagination errors documented. |
| 6 | Evidence Grading | **PASS** | 11 claims individually graded (0.35–0.95). Modifiers applied with justification. Median correctly computed (0.60). |
| 7 | GoF Filter | **PASS** | TP53 loss is loss-of-function, not GoF. Report correctly identified MDM2 inhibitor mechanism mismatch (requires WT-TP53) and applied −0.20 modifier. Analogous filtering correctly executed. |
| 8 | Trial Validation | **PASS** | All 5 NCT IDs verified via clinicaltrials_get_trial. "Verified" column = Yes for all rows. |
| 9 | Completeness | **PASS** | CQ fully answered: (a) SL gene pairs validated via CRISPR ORCS data, (b) druggable opportunities identified with 7 compounds across 4 targets, (c) clinical trial evidence provided. |
| 10 | Hallucination Risk | **LOW** | No unsourced statistics, no fabricated NCT IDs, no FDA approval years without citation. Synthesis disclaimer included. Mechanism descriptions faithfully paraphrase KG edge properties. |

---

## Detailed Findings

### Dimension 1: CURIE Resolution

**Verdict**: PARTIAL
**Score**: 8/10

**Evidence checked**: Report Resolved Entities table (lines 30–38), KG JSON nodes array (lines 23–142), compound nodes (lines 143–214).

**Positive observations**:
- All 8 gene entities resolved to canonical CURIEs with correct prefix format (HGNC:11998, not 11998)
- Cross-references (Ensembl, UniProt, Entrez) provided for all genes
- ATR and POLQ correctly documented as Entrez-resolved (NCBIGene:545, NCBIGene:10721) with explanation for why HGNC resolution failed (short symbol noise)

**Issues found**:
- Compound nodes in KG use custom CURIEs (COMPOUND:ADAVOSERTIB, COMPOUND:PREXASERTIB) rather than canonical CHEMBL CURIEs. The Open Targets knownDrugs query would have returned CHEMBL molecule IDs. These were not captured in the KG or report.
- This is a **protocol gap** (Phase 4a did not capture CHEMBL IDs from OT output) rather than a report formatting issue.

**Recommendation**: In future pipeline runs, extract `drugId` (CHEMBL CURIE) from Open Targets knownDrugs response and use as compound node ID.

---

### Dimension 2: Source Attribution

**Verdict**: PASS
**Score**: 9/10

**Evidence checked**: All tables and narrative sections in the report.

**Positive observations**:
- Every row in Drug Candidates, Clinical Trials, CRISPR Essentiality, and Disease Associations tables includes source citations
- Mechanism Rationale section cites specific tool calls (get_article_metadata, get_orcs_essentiality, clinicaltrials_get_trial)
- Gaps section uses `[No data: ...]` format for missing results (e.g., volasertib TP53 trials)
- Synthesis disclaimer included at top of report

**Minor gaps**:
- STRING interaction table cites the source once in the section header rather than per-row. Acceptable for a single-source table but could be more granular.
- Pathway context table cites `wikipathways_get_pathways_for_gene(TP53)` — correct but uses the general call rather than specific pathway retrieval calls.

---

### Dimension 3: LOCATE→RETRIEVE Discipline

**Verdict**: PARTIAL
**Score**: 7/10

**Evidence checked**: Report Resolved Entities source column, KG JSON entity provenance, conversation context (from summary).

**Positive observations**:
- RETRIEVE steps clearly cited: `hgnc_get_gene(HGNC:12761)`, `entrez_get_gene(NCBIGene:10721)`, etc.
- For ATR and POLQ, the report documents the LOCATE difficulty (short symbols returning wrong genes) and the fallback to Entrez search — good transparency

**Issues found**:
- Resolved Entities table source column cites only RETRIEVE tools (hgnc_get_gene, entrez_get_gene). The preceding LOCATE calls (hgnc_search_genes, entrez_search_genes) are not cited in the table.
- **Classification**: Presentation failure, not protocol failure. The conversation summary confirms all entities went through LOCATE before RETRIEVE. The knowledge graph confirms all entities exist with valid CURIEs.

**Recommendation**: Include both LOCATE and RETRIEVE citations in Resolved Entities table, e.g., `[Sources: hgnc_search_genes("WEE1"), hgnc_get_gene(HGNC:12761)]`.

---

### Dimension 4: Disease CURIE in ENRICH Phase

**Verdict**: PARTIAL
**Score**: 6/10

**Evidence checked**: Report Resolved Entities table, Disease Associations section, KG JSON disease_associations object.

**Template requirement**: Template 1 — Disease CURIE is **REQUIRED**.

**Positive observations**:
- Disease Associations section includes 8 diseases with proper MONDO/EFO IDs (e.g., MONDO_0018875 for Li-Fraumeni syndrome, EFO_0000182 for HCC)
- Scores from Open Targets reported with source citation
- KG JSON contains disease_associations.top_diseases array with IDs

**Issues found**:
- No disease entity appears as a row in the Resolved Entities table. Template 1 requires disease CURIEs in the primary entity table.
- KG JSON stores diseases in a separate `disease_associations` object rather than as formal graph nodes. This means they weren't resolved as first-class entities during Phase 2 ENRICH.
- The report partially compensates by including a full Disease Associations section, but the formal requirement is not met.

**Classification**: Protocol gap (diseases not resolved as graph nodes) + Presentation failure (not in Resolved Entities table). Severity: Moderate.

**Recommendation**: Add a "TP53-mutant cancers" disease entity row to Resolved Entities (e.g., using EFO or MONDO CURIE for the broadest applicable cancer term). In the KG, promote top disease associations to formal graph nodes.

---

### Dimension 5: Open Targets Pagination

**Verdict**: PASS
**Score**: 9/10

**Evidence checked**: KG JSON compound node sources, conversation summary (Phase 4a details).

**Positive observations**:
- Open Targets GraphQL used via curl for knownDrugs queries on 4 targets (WEE1, CHEK1, PLK1, MDM2)
- Multiple drugs retrieved per target (2 for WEE1 implied, 3 for CHEK1, 2 for PLK1, 4+ for MDM2)
- No pagination errors or truncation artifacts observed

**Notes**: GraphQL queries handle pagination differently from REST APIs. The `size` parameter in the knownDrugs query controls result count. No evidence of the `page`/`index` anti-pattern.

---

### Dimension 6: Evidence Grading

**Verdict**: PASS
**Score**: 10/10

**Positive observations**:
- 11 claims individually graded with numeric scores
- Base levels correctly assigned (L1–L4) based on evidence criteria
- Modifiers applied with explicit justification:
  - +0.10 mechanism match (adavosertib, prexasertib, volasertib)
  - +0.05 literature support (Feng 2022 PMID)
  - +0.05 high STRING score (MDM2 interaction)
  - −0.20 mechanism mismatch (MDM2 inhibitors in TP53-mutant context)
  - −0.10 single source (POLQ, ATR)
  - −0.10 no TP53-specific trial (volasertib)
- Median confidence correctly computed as 0.60 (not mean)
- Range reported: 0.35–0.95
- Distribution summary provided (1×L4, 2×L3, 6×L2, 2×L1)
- No claims below the L1 threshold (0.30)

This is an exemplary evidence grading section.

---

### Dimension 7: Gain-of-Function Filter

**Verdict**: PASS (context-adapted)
**Score**: 9/10

**Evidence checked**: Report Drug Candidates table, Mechanism Rationale MDM2 section, Evidence Assessment claim #7.

**Context**: TP53 mutations are loss-of-function (tumor suppressor loss), not gain-of-function. The standard GoF filter (exclude agonists for GoF diseases) does not directly apply.

**Positive observations**:
- The report correctly identified an analogous mechanism mismatch: MDM2 antagonists restore wild-type p53 function, which is impossible when TP53 is mutant/absent
- Applied −0.20 mechanism mismatch modifier to idasanutlin (claim #7)
- MDM2 inhibitors explicitly flagged as "NOT suitable for TP53-mutant cancers" in Drug Candidates table and Mechanism Rationale
- Separate asterisk annotation explains the contraindication

This represents thoughtful biological reasoning beyond the standard GoF filter template.

---

### Dimension 8: Trial Validation

**Verdict**: PASS
**Score**: 10/10

**Evidence checked**: Report Clinical Trials table, KG JSON trial nodes (lines 252–324), clinical_trials array (lines 389–395).

**Positive observations**:
- All 5 NCT IDs verified via `clinicaltrials_get_trial` (cited in source column)
- "Verified" column = "Yes" for all 5 trials
- KG JSON trial nodes include `"validation": "VALIDATED"` for all entries
- TP53-specific enrollment correctly annotated (3 of 5 trials)
- Trial status accurately captured (2 COMPLETED, 2 TERMINATED, 1 COMPLETED)
- Idasanutlin trial correctly noted as "Terminated for futility — requires TP53 wild-type"

---

### Dimension 9: Completeness

**Verdict**: PASS
**Score**: 9/10

**Evidence checked**: CQ text vs. report sections.

**CQ components**:

| Component | Addressed? | Report Section |
|-----------|-----------|---------------|
| Validate SL gene pairs from Feng et al. | Yes | CRISPR Essentiality Validation (BioGRID ORCS) |
| Identify druggable opportunities | Yes | Drug Candidates (7 compounds, 4 targets) |
| TP53-mutant cancer context | Yes | Mechanism Rationale, Clinical Trials (TP53-specific enrollment) |
| Reference paper grounding | Yes | Resolved Entities (PMID: 35559673 cited) |

**Minor gap**: USP28 (HGNC:12625) documented as located but not enriched. This is appropriately flagged in Gaps and Limitations (item 1) rather than silently omitted.

---

### Dimension 10: Hallucination Risk

**Verdict**: **LOW**
**Score**: 9/10

**Systematic check**:

| Check | Result |
|-------|--------|
| Unsourced statistics (prevalence, percentages) | None found |
| Fabricated NCT IDs | None — all 5 verified via clinicaltrials_get_trial |
| FDA approval years without source | None |
| Drug names not from tool output | None — all 7 drugs traced to Open Targets knownDrugs |
| Gene functions from training knowledge | None — mechanism descriptions paraphrase KG edge properties |
| Ungrounded mechanistic claims | None beyond synthesis of cited tool output |

**Paraphrasing assessment**: The Mechanism Rationale section paraphrases KG edge mechanism descriptions (e.g., "TP53-mutant cells depend on WEE1-mediated G2/M checkpoint arrest" is a faithful synthesis of the KG edge property `"mechanism": "TP53-mutant cells depend on WEE1-mediated G2/M checkpoint; WEE1 inhibition causes mitotic catastrophe"`). This is acceptable synthesis per the review framework.

**One borderline item**: The Mechanism Rationale states "WEE1 inhibition by adavosertib forces TP53-mutant cells into mitosis with unrepaired DNA, causing mitotic catastrophe and cell death." The KG edge says "WEE1 inhibition causes mitotic catastrophe" — the report adds "with unrepaired DNA" as interpretive detail. This is a faithful biological inference from the SL mechanism description, not a fabricated claim, but it slightly extends the tool output. Flagged as acceptable synthesis.

---

## Failure Classification

| # | Dimension | Score | Failure Type | Severity | Recommendation |
|---|-----------|-------|-------------|----------|----------------|
| 1 | CURIE Resolution | PARTIAL | Protocol gap | Moderate | Capture CHEMBL CURIEs from OT knownDrugs in Phase 4a |
| 3 | LOCATE→RETRIEVE | PARTIAL | Presentation failure | Minor | Cite both search and get tool calls in Resolved Entities table |
| 4 | Disease CURIE | PARTIAL | Protocol gap + Presentation | Moderate | Add disease entity to Resolved Entities; promote to graph node |

---

## Overall Assessment

### Protocol Execution Quality: 8/10

The Fuzzy-to-Fact pipeline executed comprehensively across all 8 phases. Entity resolution, CRISPR validation, drug traversal, trial discovery, and validation were all performed correctly. Two protocol-level gaps: (1) CHEMBL CURIEs not captured for compounds, and (2) disease entities not promoted to first-class graph nodes. Both are moderate issues that don't undermine the scientific validity of the findings.

### Report Presentation Quality: 8/10

The report is well-structured, thoroughly sourced, and follows Template 1 conventions closely. Evidence grading is exemplary — 11 individually scored claims with justified modifiers and correct median computation. The MDM2 mechanism mismatch analysis demonstrates sophisticated biological reasoning. Presentation gaps (LOCATE citations, disease in Resolved Entities) are minor and documented transparently.

### Overall Verdict: **PASS**

The report successfully answers the competency question with strong evidence grounding. The most clinically validated finding (adavosertib/WEE1 in TP53-mutant cancers at L4 confidence) is well-supported by both CRISPR screen data and completed Phase II trials. The three PARTIAL dimensions reflect moderate gaps that do not compromise the report's scientific rigor or practical utility.

---

## Next Steps

Given the **PASS** verdict, the report is ready for the publication pipeline:

- Run `/ob-publish` to generate the full publication package (Synapse grounding → quality review → BioRxiv preprint draft)

---

*Quality review generated by Fuzzy-to-Fact Quality Review Framework v1.0*
